Menu
Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 11 » Issue 1
Endocan and the respiratory system: a review
Authors Kechagia M, Papassotiriou I, Gourgoulianis KI
Received 2 August 2016
Accepted for publication 20 September 2016
Published 12 December 2016 Volume 2016:11(1) Pages 3179—3187
DOI https://doi.org/10.2147/COPD.S118692
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 3
Editor who approved publication: Dr Richard Russell
Maria Kechagia,1,2 Ioannis Papassotiriou,2 Konstantinos I Gourgoulianis1
1Respiratory Medicine Department, University of Thessaly Medical School, Larissa, 2Department of Clinical Biochemistry, Aghia Sophia Children’s Hospital, Athens, Greece
Abstract: Endocan, formerly called endothelial cell-specific molecule 1, is an endothelial cell-associated proteoglycan that is preferentially expressed by renal and pulmonary endothelium. It is upregulated by proangiogenic molecules as well as by pro-inflammatory cytokines, and since it reflects endothelial activation and dysfunction, it is regarded as a novel tissue and blood-based relevant biomarker. As such, it is increasingly being researched and evaluated in a wide spectrum of healthy and disease pathophysiological processes. Here, we review the present scientific knowledge on endocan, with emphasis on the evidence that underlines its possible clinical value as a prognostic marker in several malignant, inflammatory and obstructive disorders of the respiratory system.
Keywords: endocan, endothelial dysfunction, inflammation, respiratory disorders
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.